← All trials
NCT06048692
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2023
- Primary completion
- Sep 15, 2023
- Completion date
- Sep 20, 2023
- First posted
- Sep 21, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 213
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beni Suef UniversityLead sponsor
- Beni Suef UniversityOverall official - principal investigator
- Beni Suef UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.